Zimmer Biomet raised FY2026 organic constant currency revenue guidance to 2.25% to 3.25% from 1% to 3% and adjusted EPS guidance to $8.47 to $8.59.
Monogram mBôs autonomous robotics program is moving toward a near-term 510(k) filing, with the semi-autonomous launch expected in early 2027 and the fully autonomous version in late 2027 or early 2028.
The iodine-coated hip implant in Japan is expected to convert the majority of the market and expand to additional geographies, supporting second-half 2026 growth.
The new Costa Rica manufacturing plant is under construction, with initial manufacturing lines scheduled to be established next year.
Next-generation ROSA Shoulder is entering full market release within weeks, with plans to scale deployments in the U.S. and other markets.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Zimmer Biomet Holdings, Inc. and 4,900+ companies.